Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Mon, 20.01.2025
Formycon AG
Press Release // January 20, 2025
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
FYB203 (aflibercept) approved for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
AHZANTIVE® and Baiama® offer patients treat [ … ]
Wed, 15.01.2025
Formycon AG
Press Release // January 15, 2025
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Otulfi®received MHRA approval for both subcutaneous and intravenous formulations, to treat serious inflammatory diseases
UK approval follows the series of successful approvals by the FDA, the European Co [ … ]
Mon, 13.01.2025
Formycon AG
Presse Release // January 13, 2025
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Planegg-Martinsried, Germany – Klinge Biopharma GmbH (Klinge), the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimila [ … ]
Thu, 09.01.2025
Formycon AG
Press Release // January 9, 2025
Formycon included in TecDAX Index of Deutsche Börse
Formycon to join the ranks of the 30 leading listed technology companies
Uplisting to the Prime Standard, inclusion in the SDAX, and robust business development further enhance the stock’s appeal
Entry into the TecDAX becomes effective as of January 13, 2025
[ … ]
Wed, 08.01.2025
Formycon AG
Press Release // January 8, 2025
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Otulfi® approved by Health Canada for both subcutaneous and intravenous formulations to treat serious inflammatory diseases
Health Canada joins the FDA and the European Commission in gra [ … ]